Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study

Table 1 Main characteristics of the eligible studies from systematic review

First author	Country	Stage	Age	Abs	Cut off scores (IHC)	Cancer	Poor	Moderate/well	Stage 3–4	Stage 1–2	Node +	Node ^_	Serous	Non-serous	Survival rate	Clinical outcomes
First author	Country	Stage	Age	Abs	Cut off scores (IHC)	N (E+ %)	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	E+/N	Survival rate	Clinical outcomes
Hamanishi 2007 [12]	Japan	1–4	55	Clone 27A2	Scores 2 and 3	70 (68.6%)			29/39	19/31	11/14	37/56	21/28	27/42	5-year	OS, PFS
Darb-Esfahani 2016 [28]	Germany	1–4	60	Clone EPR1161	IRS 1–12	215 (93.9%)									5-year	OS, PFS
Webb 2016 [27]	Canada	1–3	NA	Cone SP142	1%	490 (34.9%)	108/278	63/212	37/83	134/407			112/206	59/284	10-year	DSS
Li 2017 [21]	China	1–4	NA	Ventana	Scores 3–6	140 (25%)									5-year	PFS
Mesnage 2017 [26]	France	2–4	NA	Clone E1L3N	5%	50 (30%)			14/49	1/1
Chatterjee 2017 [25]	UK	NA	NA	Dako	Median	48 (NA)									5-year	PFS
Li 2017 [21]	China	1–4	NA	SP263	Scores 2 and 3	209 (15.8%)			15/128	18/81			13/113	20/95	5-year	OS
Wang 2017 [23]	China	1–4	57	Clone E1L3N	5%	107 (24.3%)			24/81	2/26					5-year	OS
Zhu 2017 [22]	China	1–4	53	ab205921	10%	122 (44.3%)			27/47	27/75					5-year	OS, PFS
Mills 2018 [13]	USA	1–4	NA	Clone SP142	1%	112 (28.6%)			26/92	6/19					3-year	OS
Drakes 2018 [20]	USA	1–4	61	ab205921	Scores 2–4	55 (32.7%)	17/41	1/13	13/46	5/9
Zhu 2018 [19]	China	1–4	53	Clone SP142	10%	112 (58.9%)	10/16	46/80	41/70	25/42	20/31	37/63	45/75	21/37	5-year	DFS, OS

IHC immunohistochemistry, NA not applicable, Ab antibody, E+ positive expression, N the number of the study population, IRS immuno-reactivity score, OS overall survival, DS disease-specific survival, DFS disease-free survival, PFS progression-free survival

ISSN: 1757-2215